Nilofar Islam, MD
Clinical Cardiac Electrophysiology · Towson, MDNPI 1588644074
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Boston Scientific at 54.5% of the total. Reporting peaked in 2022 at $25,106 and has fallen 84.4% since, to $3,906 in 2025.
Across 289 payments — averaging $212.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$33K
- Cook Incorporated$12K
- Abbott$10K
- Medtronic$2K
- Cook Medical LLC$1K
- Biosense Webster, Inc.$564
- plus $2K from 25 others
Across 56 payments — averaging $2425.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$88K
- Abbott$48K
What the payments were for
- Consulting fees$17,23028%
- Speaking & faculty fees$25,97542%
- Travel & lodging$8,36614%
- Food & beverage$9,81916%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 52 | $33,450 |
| Cook Incorporated | 5 | $12,205 |
| Abbott | 74 | $9,953 |
| Medtronic(2 entities) | 55 | $2,071 |
| Cook Medical LLC | 11 | $1,348 |
| Biosense Webster, Inc. | 17 | $564 |
| Cardiva Medical, Inc. | 4 | $242 |
| Pfizer | 11 | $216 |
| E.r. Squibb & Sons, L.L.C. | 11 | $205 |
| Edwards Lifesciences | 4 | $144 |
| Boehringer Ingelheim | 4 | $119 |
| Johnson & Johnson | 6 | $102 |
| AstraZeneca | 5 | $95 |
| Baxter Healthcare | 2 | $90 |
| Philips North America LLC | 3 | $79 |
| Actelion Pharmaceuticals US, Inc. | 3 | $71 |
| Merck | 3 | $60 |
| Scpharmaceuticals Inc. | 3 | $55 |
| Novo Nordisk | 2 | $49 |
| Terumo Medical Corporation | 2 | $36 |
| Biotronik Inc. | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 1 | $31 |
| Atricure, Inc. | 1 | $27 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Amgen | 1 | $22 |
| Bayer | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Teleflex LLC | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$18,588
- Evolution$12,890
- WATCHMAN FLX$7,500
- Watchman$6,545
- Accent Pacemaker$3,375
- AVEIR$2,809
- Cook$471
- Micra$447
- ENSITE PRECISION$275
- Confirm Rx$181
- ASSURITY$181
- Cardiva VASCADE MVP VVCS 6-12F$180
- MyCareLink$140
- OMNIASECURE MRI SURESCAN$120
- MitraClip$106
- Cook Medical Lead Management - Lead Extraction$101
How this compares
$61,405 in reported general payments places this provider in the 85th percentile of 63 clinical cardiac electrophysiology providers in Maryland.
See all clinical cardiac electrophysiology providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 146 | $155,319 |
| Bisoprolol Fumarate | 177 | $4,918 |
| Metoprolol Succinate | 293 | $4,183 |
| Amiodarone Hcl | 72 | $2,167 |
| Flecainide Acetate | 36 | $2,123 |
| Dofetilide | 11 | $1,858 |
| Losartan Potassium | 62 | $602 |
| Cephalexin | 82 | $351 |
| Carvedilol | 19 | $268 |
| Atorvastatin Calcium | 12 | $262 |
| Lisinopril | 18 | $250 |
| Amlodipine Besylate | 55 | $158 |
| Furosemide | 25 | $96 |
| Olmesartan Medoxomil | 12 | $84 |
| Rosuvastatin Calcium | 11 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $216 | $155,319146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 63 clinical cardiac electrophysiology providers in Maryland.
Other clinical cardiac electrophysiology in Towson
- Vikas KalraTowson$17K
- David EdwardsTowson$10K
- Sean BeinartRockville$315K
- Charles LoveBaltimore$238K
- Hugh CalkinsBaltimore$202K
- Paresh ShahBaltimore$97K
- Helen BaroldRockville$83K
- Jonathan ChrispinBaltimore$77K
- Sung LeeTakoma Park$68K
- Stephen ShorofskyBaltimore$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.